Guangdong Biolight Meditech Co., Ltd. (SHE:300246)
China · Delayed Price · Currency is CNY 13.23
-0.19 (-1.42%)
At close: Feb 13, 2026
SHE:300246 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,034 | 1,048 | 1,178 | 1,164 | 1,074 | 1,386 |
Other Revenue | 12.68 | 12.68 | 16.18 | 19.98 | 16.74 | 10.39 |
| 1,046 | 1,060 | 1,194 | 1,184 | 1,091 | 1,396 | |
Revenue Growth (YoY) | -0.34% | -11.18% | 0.87% | 8.49% | -21.85% | 69.02% |
Cost of Revenue | 787 | 782.58 | 813.77 | 828.57 | 735.25 | 745.9 |
Gross Profit | 259.19 | 277.9 | 380.23 | 355.13 | 355.76 | 650.11 |
Selling, General & Admin | 244.05 | 262.01 | 254.91 | 263.77 | 201.69 | 156.03 |
Research & Development | 72.13 | 76.92 | 85.85 | 87.54 | 74.34 | 57.17 |
Other Operating Expenses | 5.1 | 0.63 | -3.72 | 3.96 | 3.63 | 6.34 |
Operating Expenses | 327.04 | 343.79 | 342.86 | 361.77 | 283.17 | 222.18 |
Operating Income | -67.85 | -65.89 | 37.37 | -6.64 | 72.6 | 427.93 |
Interest Expense | -26.49 | -27.38 | -14.88 | -11.52 | -11.98 | -12.52 |
Interest & Investment Income | 17.16 | 23.54 | 22.44 | 16.07 | 7.94 | 4.29 |
Currency Exchange Gain (Loss) | 5.19 | 5.19 | 1.59 | 1.75 | -1.07 | -11.87 |
Other Non Operating Income (Expenses) | 7.19 | -3.16 | -2.24 | -0.95 | -3.42 | -3.18 |
EBT Excluding Unusual Items | -64.79 | -67.69 | 44.29 | -1.29 | 64.07 | 404.65 |
Impairment of Goodwill | -11.4 | -11.4 | -90.57 | - | -9.46 | - |
Gain (Loss) on Sale of Investments | -0.02 | - | - | - | -0.45 | - |
Gain (Loss) on Sale of Assets | -0.88 | -0.02 | -0.31 | 0.51 | 0.92 | -0.06 |
Asset Writedown | -9.71 | -9.42 | -23.98 | -0.01 | -0.08 | -1.9 |
Legal Settlements | -2.19 | -2.19 | -1.81 | - | - | - |
Other Unusual Items | 19.6 | 19.6 | 26.23 | 22.94 | 22.87 | 14.5 |
Pretax Income | -69.39 | -71.12 | -46.16 | 22.14 | 77.88 | 417.19 |
Income Tax Expense | -6.61 | -1.08 | 14.8 | -2.49 | 10.62 | 64.93 |
Earnings From Continuing Operations | -62.78 | -70.04 | -60.96 | 24.62 | 67.26 | 352.26 |
Minority Interest in Earnings | -3.37 | -1.4 | -4.23 | -2.49 | -3.47 | -6.11 |
Net Income | -66.14 | -71.44 | -65.19 | 22.13 | 63.79 | 346.15 |
Net Income to Common | -66.14 | -71.44 | -65.19 | 22.13 | 63.79 | 346.15 |
Net Income Growth | - | - | - | -65.31% | -81.57% | 434.90% |
Shares Outstanding (Basic) | 264 | 263 | 264 | 261 | 219 | 219 |
Shares Outstanding (Diluted) | 264 | 263 | 264 | 261 | 219 | 220 |
Shares Change (YoY) | 1.95% | -0.51% | 1.23% | 18.96% | -0.26% | 0.26% |
EPS (Basic) | -0.25 | -0.27 | -0.25 | 0.08 | 0.29 | 1.58 |
EPS (Diluted) | -0.25 | -0.27 | -0.25 | 0.08 | 0.29 | 1.58 |
EPS Growth | - | - | - | -70.84% | -81.52% | 433.53% |
Free Cash Flow | -88.5 | -112.45 | -91.29 | -71.08 | -82.8 | 387.33 |
Free Cash Flow Per Share | -0.34 | -0.43 | -0.35 | -0.27 | -0.38 | 1.76 |
Dividend Per Share | 0.050 | - | - | 0.133 | 0.133 | 0.267 |
Dividend Growth | - | - | - | - | -50.02% | 100.08% |
Gross Margin | 24.77% | 26.21% | 31.85% | 30.00% | 32.61% | 46.57% |
Operating Margin | -6.49% | -6.21% | 3.13% | -0.56% | 6.65% | 30.65% |
Profit Margin | -6.32% | -6.74% | -5.46% | 1.87% | 5.85% | 24.80% |
Free Cash Flow Margin | -8.46% | -10.60% | -7.65% | -6.00% | -7.59% | 27.75% |
EBITDA | -3.89 | -7.76 | 87.72 | 37.67 | 108.7 | 445.62 |
EBITDA Margin | -0.37% | -0.73% | 7.35% | 3.18% | 9.96% | 31.92% |
D&A For EBITDA | 63.95 | 58.13 | 50.35 | 44.31 | 36.1 | 17.69 |
EBIT | -67.85 | -65.89 | 37.37 | -6.64 | 72.6 | 427.93 |
EBIT Margin | -6.49% | -6.21% | 3.13% | -0.56% | 6.65% | 30.65% |
Effective Tax Rate | - | - | - | - | 13.63% | 15.56% |
Revenue as Reported | 1,046 | 1,060 | 1,194 | 1,184 | 1,091 | 1,396 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.